Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 705-714

  Hu, Zheng ^a   Li, Xiang ^a   Yuan, Rong ^a   Ring, Brian Z ^b   Su, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Applied Genomics Inc   (United States)

Author keywords

Breast cancer; Meta analysis; Polymorphism; Susceptibility; TP53

Indexed keywords

ADENINE; ARGININE; GUANINE; PROLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ASIA; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; EUROPE; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDITERRANEAN REGION; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEQUENCE DELETION; UNITED STATES; YOUNG ADULT;

EID: 77950863858     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0488-9     Document Type: Article

References (49)

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310. doi:10.1038/35042675
2. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev MoI Cell Biol 8: 275-283. doi:10.1038/nrm2147
3. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 2: 95-107. doi:10.1038/nrc 2584
4. Pietsch EC, Humbey O, Murphy ME (2006) Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611. doi:10.1038/sj.onc. 1209367
5. Hrstka R, Coates PJ, Vojtesek B (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13: 440-453. doi:10.1111/j.1582-4934.2008.00634.x
6. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898. doi: 10.103 8/sj.one.120 1263
7. Dumont P, Leu JI, Delia Pietra ACIII, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential, Nat Genet 33: 357-365. doi: 10.1038/ ng1093 (Pubitemid 36278852)
8. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199. doi: 10.1002/ijc.11548 (Pubitemid 37541770)
9. Salvioli S, Bonafé M, Barbi C, Storci G, Trapassi C, Tocco F, Gravina S, Rossi M, Tiberi L, Mondello C, Monti D, Franceschi C (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4: 1264-1271 (Pubitemid 41365399)
10. Siddique M, Sabapathy K (2006) Trp53-dependent DNA repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500. doi: 10.1038/sj.onc.1209405 (Pubitemid 43901670)
11. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y (2009) A metaanalysis of TP53 codon 72 polymorphism and lung cancer risk: Evidence from 15,857 subjects. Lung Cancer(ahead of print) doi: 10.1016/j.lungcan.2008.12.009
12. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121: 1481-1486. doi:10.1002/ijc.22833 (Pubitemid 47328706)
13. Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS (2004) Polymorphism p53 codon-72 and invasive cervical cancer: a metaanalysis. Int J Gynaecol Obstet 85: 301-308. doi:10.1016/j.ijgo. 2003.08.017 (Pubitemid 38622573)
14. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8: 32. doi: 10.1186/ 1471-2407-8-32
15. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23: 1954-1956. doi:10.1038/sj.onc.120 7305
16. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13: 5974-5981. doi: 10.1158/1078-0432.CCR-07-0113 (Pubitemid 47583926)
17. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316
18. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6: 105-112 (Pubitemid 27069203)
19. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12: 269-272 (Pubitemid 34596792)
20. Buyru N, Altinisik J, Demokan S, Dalay N (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31: 207-213. doi:10.1016/j.cdp.2007.04.004 (Pubitemid 47248151)
21. Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18: 48-57. doi:10.1016/j.annepidem.2007.06.006 (Pubitemid 350184342)
22. Menzel HJ, Sarmanova J, Souček P, Berberich R, Grünewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90: 1989-1994. doi:10.1038/sj.bjc.6601779 (Pubitemid 38746342)
23. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92: 1144-1148. doi:10.1038/sj.bjc. 6602451 (Pubitemid 40546682)
24. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst EB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van't Veer LJ, Breast Cancer Association Consortium (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? a large pooled series from the breast cancer association consortium. Cancer Res 67: 9584-9590. doi: 10.1158/0008-5472.CAN-07-0738
25. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case-control study. Carcinogenesis 28: 1680-1686. doi:10.1093/carcin/bgm097 (Pubitemid 47289028)
26. The Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the breast cancer association consortium. J Natl Cancer Inst 98: 1382-1396. doi:10.1093/jnci/djj374
27. American Cancer Society (2007) Global cancer facts and Figs 2007. American Cancer Society Inc, USA
28. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, Wei Q (2007) Polymorphic T53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 4300-4305. doi:10.1158/1078-0432. CCR-07-0469 (Pubitemid 47105994)
29. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210: 197-203. doi:10.1016/j.canlet. 2004.03.031 (Pubitemid 38748690)
30. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy N (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112: 81-87. doi : 10.1007/s10549-007-9821-3
31. Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 Codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392. doi: 10.1006/ mcbr.2000.0241
32. Garcia-Closas M, Kristensen V, Langerod A, Qi Y, Yeager M, Burdett L, Welch R, Lissowska J, Peplonska B, Brinton L, Gerhard DS, Gram IT, Perou CM, Borresen-Dale AL, Chanock S (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121: 2532-2538. doi: 10.1002/ijc.22985 (Pubitemid 350022425)
33. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM, SEARCH breast cancer study (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27. doi: 10.1186/bcr1669
34. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14: 1085-1089
35. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C 14-to-A4T14 at Exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast cancer 10(4): 307-311
36. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA, Das BC (2003) Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252: 117-124
37. Siddique MM, Balram. C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14: 2245-2252. doi: 10.1158/1055-9965.EPI-05-0153
38. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q, Shen H (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27: 766-771. doi:10.1093/carcin/bgi295
39. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173: 38-42. doi:10.1016/j.cancergencyto. 2006.09.010
40. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN (2007) Implication of BRCA2 -26G > A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res 9: R71. doi:10.1186/bcr1780
41. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K (2008) MDM2 SNP309 G allele increases risk but the Tallele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29: 754-761. doi:10.1093/carcin/bgn024 (Pubitemid 351494162)
42. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010: 764-770 (Pubitemid 38265078)
43. Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN (2003) Evidence against involvement of P53 polymorphism in breast cancer predisposition. Int J Cancer 103: 431-433. doi: 10.1002/ijc.10834 (Pubitemid 36076439)
44. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222: 57-65. doi:10.1016/j.canlet.2004.11.025
45. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103. doi:10.1158/1078-0432.CCR-05-0173 (Pubitemid 41003693)
46. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16: 1051-1057. doi:10.1093/hmg/ddm050 (Pubitemid 47062726)
47. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8: 96. doi: 10.1186/1471-2407-8-96 (Pubitemid 351587049)
48. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 18: 621-625. doi:10.1007/s10552-007-9004-x
49. Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbonrelated exposures, and breast cancer risk among women on Long Island, New York, Breast Cancer Res Treat 108: 93-99. doi: 10.1007/s10549-007-9573-0